|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murray N: Reality check for pemetrexed and
maintenance therapy in advanced non-small-cell lung cancer. J Clin
Oncol. 32:482–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herbst RS, Heymach JV and Lippma SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Claassens L, van Meerbeeck J, Coens C,
Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G and Bottomley
A: Health-related quality of life in non-small-cell lung cancer: An
update of a systematic review on methodologic issues in randomized
controlled trials. J Clin Oncol. 29:2104–2120. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu
Y, Chen Y, Xu L, Zen K, Zhang C and Shen H: Serum microRNA
signatures identified in a genome-wide serum microRNA expression
profiling predict survival of non-small-cell lung cancer. J Clin
Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shtivelman E, Hensing T, Simon GR, Dennis
PA, Otterson GA, Bueno R and Salgia R: Molecular pathways and
therapeutic targets in lung cancer. Oncotarget. 5:1392–1433. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scagliotti GV and Novello S: Adjuvant
therapy in completely resected non-small-cell lung cancer. Curr
Oncol Rep. 5:318–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li L, Chen YY, Li SQ, Huang C and Qin YZ:
Expression of miR-148/152 family as potential biomarkers in
non-small-cell lung cancer. Med Sci Monit. 21:1155–1161. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Socinski MA: Seeking new options for the
treatment of small-cell lung cancer. Lung cance. 50 Suppl
1:S25–S26. 2005. View Article : Google Scholar
|
|
11
|
Ranganathan K and Sivasankar V:
MicroRNAs-Biology and clinical applications. J Oral Maxillofac
Pathol. 18:229–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li MH, Fu SB and Xiao HS: Genome-wide
analysis of microRNA and mRNA expression signatures in cancer. Acta
Pharmacol Sin. 36:1200–1211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rutnam ZJ and Yang BB: The involvement of
microRNAs in malignant transformation. Histol Histopathol.
27:1263–1270. 2012.PubMed/NCBI
|
|
14
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zimmerman AL and Wu S: MicroRNAs, cancer
and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kishikawa T, Otsuka M, Ohno M, Yoshikawa
T, Takata A and Koike K: Circulating RNAs as new biomarkers for
detecting pancreatic cancer. World J Gastroenterol. 21:8527–8540.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Skrzypski M, Dziadziuszko R and Jassem J:
MicroRNA in lung cancer diagnostics and treatment. Mutat Res.
717:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang P, Zhuang L, Zhang J, Fan J, Luo J,
Chen H, Wang K, Liu L, Chen Z and Meng Z: The serum miR-21 level
serves as a predictor for the chemosensitivity of advanced
pancreatic cancer and miR-21 expression confers chemoresistance by
targeting FasL. Mol Oncol. 7:334–345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang X and Chen Z: MicroRNA-19a functions
as an oncogenic microRNA in non-small cell lung cancer by targeting
the suppressor of cytokine signaling 1 and mediating STAT3
activation. Int J Mol Med. 35:839–846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun W, Ma Y, Chen P and Wang D:
MicroRNA-10a silencing reverses cisplatin resistance in the
A549/cisplatin human lung cancer cell line via the transforming
growth factor-beta/Smad2/STAT3/STAT5 pathway. Mol Med Rep.
11:3854–3859. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang MX: Down-expression of circulating
micro ribonucleic acid (miRNA)-148/152 family in plasma samples of
non-small cell lung cancer patients. J Cancer Res Ther. 12:671–675.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu
RX, Liu SH, Yi QT, Li J and Song CH: Serum miR-152, miR-148a,
miR-148b and miR-21 as novel biomarkers in non-small cell lung
cancer screening. Tumour Biol. 36:3035–3042. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie WY, Zhou XD, Yang J, Chen LX and Ran
DH: Inhibition of autophagy enhances heat-induced apoptosis in
human non-small cell lung cancer cells through ER stress pathways.
Arch Biochem Biophys. 607:55–66. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Orso F, Quirico L, Virga F, Penna E,
Dettori D, Cimino D, Coppo R, Grassi E, Elia AR, Brusa D, et al:
miR-214 and miR-148b Targeting Inhibits dissemination of melanoma
and breast cancer. Cancer Res. 76:5151–5162. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song Y, Sun J, Xu Y, Liu J, Gao P, Chen X,
Zhao J and Wang Z: Microarray analysis of long non-coding RNAs
related to microRNA-148b in gastric cancer. Neoplasma. 64:199–208.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang R, Ye F, Zhen Q, Song T, Tan G, Chu
W, Zhang Y, Lv B, Zhao X and Liu J: MicroRNA-148b is a potential
prognostic biomarker and predictor of response to radiotherapy in
non-small-cell lung cancer. J Physiol Biochem. 72:337–343. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kharbanda A, Rajabi H, Jin C, Alam M, Wong
KK and Kufe D: MUC1-C confers EMT and KRAS independence in mutant
KRAS lung cancer cells. Oncotarget. 5:8893–8905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Casas E, Kim J, Bendesky A, Ohno-Machado
L, Wolfe CJ and Yang J: Snail2 is an essential mediator of
Twist1-induced epithelial mesenchymal transition and metastasis.
Cancer Res. 71:245–254. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karamitopoulou E, Zlobec I, Panayiotides
I, Patsouris ES, Peros G, Rallis G, Lapas C, Karakitsos P,
Terracciano LM and Lugli A: Systematic analysis of proteins from
different signaling pathways in the tumor center and the invasive
front of colorectal cancer. Human Pathol. 42:1888–1896. 2011.
View Article : Google Scholar
|
|
34
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
You S, Li R, Park D, Xie M, Sica GL, Cao
Y, Xiao ZQ and Deng X: Disruption of STAT3 by niclosamide reverses
radioresistance of human lung cancer. Mol Cancer Ther. 13:606–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kumper S, Mardakheh FK, McCarthy A, Yeo M,
Stamp GW, Paul A, Worboys J, Sadok A, Jørgensen C, Guichard S and
Marshall CJ: Rho-associated kinase (ROCK) function is essential for
cell cycle progression, senescence and tumorigenesis. ELife.
5:e129942016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vigil D, Kim TY, Plachco A, Garton AJ,
Castaldo L, Pachter JA, Dong H, Chen X, Tokar B, Campbell SL and
Der CJ: ROCK1 and ROCK2 are required for non-small cell lung cancer
anchorage-independent growth and invasion. Cancer Res.
72:5338–5347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li J, Song Y, Wang Y, Luo J and Yu W:
MicroRNA-148a suppresses epithelial-to-mesenchymal transition by
targeting ROCK1 in non-small cell lung cancer cells. Mol Cell
Biochem. 380:277–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cimino D, De Pittà C, Orso F, Zampini M,
Casara S, Penna E, Quaglino E, Forni M, Damasco C, Pinatel E, et
al: miR148b is a major coordinator of breast cancer progression in
a relapse-associated microRNA signature by targeting ITGA5, ROCK1,
PIK3CA, NRAS and CSF1. FASEB J. 27:1223–1235. 2013. View Article : Google Scholar : PubMed/NCBI
|
